Medication Assisted Treatment (MA.T)
BUPRENORPHINE
Buprenorphine is an opioid agonist / antagonist medication used to treat OPIOID USE DISORDER (OUD). Buprenorphine is maintenance therapy used to treat opioid dependency and addiction by reducing cravings and reversing withdrawal symptoms without causing euphoria or dangerous side effects. Maintenance Sub Lingual Buprenorphine or monthly Brixadi injections prevents Opioid Use Disorder (OUD) relapse. It works by attaching to the MU Endorphin neurotransmitter neurons and normalizes the individuals life and allows the individual to focus on their longterm recovery. Buprenorphine for OUD is used as part of a complete treatment program that also includes counseling and behavioral therapy.
Buprenorphine’s mechanism of action is that is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Dosing is individual and once the therapeutic dose has been determined, tolerance does not develop and long-term treatment is without side effects.
BUPBRIXADI: BRIXADI Is Now Available!
BRIXADI © is the only injectable buprenorphine for maintenance treatment of OPIOID USE DISORDER that may be injected subcutaneously weekly and monthly for long-term maintenance dosing options to treat patients with moderate to severe opioid use disorder (OUD)1,2 following sublingual initiation of BUPRENORPHINE / SUBOXONE© therapy.
BRIXADI © is available through a restricted distribution via the BRIXADI REMS Program and is administered only by a certified healthcare professional. BRIXADI © should never be dispensed directly to a patient because of the serious harm or death that could result from intravenous administration.1
INDICATIONS AND USAGE
BRIXADI © is indicated for the treatment of moderate to severe OPIOID USE DISORDER in patients who are already being treated with buprenorphine.
BRIXADI © should be used as part of a complete treatment plan that includes counseling and psychosocial support.
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY
- Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements.
BRIXADI utilizes FluidCrystal®* Injection Depot Technology, which is a lipid-based formulation that forms a biodegradable liquid crystalline gel upon injection and allows for1,2:
Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.
